Integra LifeSciences (IART) Tops Q2 EPS by 3c; Boosts FY16 EPS Outlook

Integra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.79, $0.03 better than the analyst estimate of $0.76. Revenue for the quarter came in at $249.3 million versus the consensus estimate of $243.17 million.

GUIDANCE:

Integra LifeSciences sees FY2016 EPS of $3.43-$3.53, versus the consensus of $3.44.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Bath & Body Works rises as Citi upgrades stock ahead of earnings